Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Efficacy and safety of zanubrutinib in patients with non-IgM lymphoplasmacytic lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

SSShenon SethiMemorial Sloan Kettering Cancer CenterABAlexander P. BoardmanMemorial Sloan Kettering Cancer CenterGSGilles SallesMemorial Sloan Kettering Cancer Center

Discussion

Loading...

Member takes

Implication

Efficacy reveals a 57% response rate in non-IgM lymphoplasmacytic lymphoma, suggesting zanubrutinib may enhance treatment options.

Key Points

  • To evaluate the efficacy and safety of zanubrutinib in patients with non-IgM lymphoplasmacytic lymphoma.
  • Screened all lymphoplasmacytic lymphoma patients treated at the center
  • Evaluated the response based on the 6th International Workshop on WM Consensus Criteria
  • Used Kaplan-Meier methods for survival analysis
  • Overall response rate was 57%, including partial responses and stable disease
  • Median progression-free survival was 92% at 2 years
  • Median overall survival was 100% at 2 years

Cite This Study

Sethi et al. (2025) studied this question.

synapsesocial.com/papers/69362f6c4fa91c937236dffahttps://doi.org/10.1182/blood-2025-5374
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Safety and efficacy of zanubrutinib in waldenstrom macroglobulinemia patients treated in common clinical practice: A retrospective-prospective study by fondazione italiana linfomi (FIL)2025
  2. 2Evaluation of real-world outcomes with zanubrutinib in patients with marginal zone lymphoma: Results from multicenter cohort study2025 · 2 citations
  3. 3Efficacy and safety of zanubrutinib in Waldenström macroglobulinemia: A systematic review and meta-analysis of clinical trials.2026
  4. 4Zanubrutinib in AL Amyloidosis Associated With Waldenström Macroglobulinemia and Other B‐Cell Non‐Hodgkin Lymphoma2026
  5. 5Spanish real-life practice confirms zanubrutinib as a safe and effective option in relapsed or refractory marginal zone lymphoma: Results of a cohort of 118 patients on behalf of GELTAMO.2025